Literature DB >> 25380603

Myelination Delay and Allan-Herndon-Dudley Syndrome Caused by a Novel Mutation in the SLC16A2 Gene.

Roberta La Piana1, Michel Vanasse2, Bernard Brais3, Genevieve Bernard4.   

Abstract

Allan-Herndon-Dudley syndrome is an X-linked disease caused by mutations in the solute carrier family 16 member 2 (SLC16A2) gene. As SLC16A2 encodes the monocarboxylate transporter 8 (MCT8), a thyroid hormone transporter, patients with Allan-Herndon-Dudley syndrome present a specific altered thyroid hormone profile. Allan-Herndon-Dudley syndrome has been associated with myelination delay on the brain magnetic resonance imaging (MRI) of affected subjects. We report a patient with Allan-Herndon-Dudley syndrome characterized by developmental delay, hypotonia, and delayed myelination caused by a novel SLC16A2 mutation (p.L291R). The thyroid hormones profile in our patient was atypical for Allan-Herndon-Dudley syndrome. The follow-up examinations showed that the progression of the myelination was not accompanied by a clinical improvement. Our paper suggests that SLC16A2 mutations should be investigated in patients with myelination delay even when the thyroid function is not conclusively altered.
© The Author(s) 2014.

Entities:  

Keywords:  Allan-Herndon-Dudley syndrome; SLC16A2; myelination delay; thyroid function

Mesh:

Substances:

Year:  2014        PMID: 25380603     DOI: 10.1177/0883073814555189

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

1.  Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice.

Authors:  Hideyuki Iwayama; Xiao-Hui Liao; Lyndsey Braun; Soledad Bárez-López; Brian Kaspar; Roy E Weiss; Alexandra M Dumitrescu; Ana Guadaño-Ferraz; Samuel Refetoff
Journal:  Thyroid       Date:  2016-08-23       Impact factor: 6.568

Review 2.  Thyroid Hormone Signaling in Oligodendrocytes: from Extracellular Transport to Intracellular Signal.

Authors:  Jae Young Lee; Steven Petratos
Journal:  Mol Neurobiol       Date:  2016-07-18       Impact factor: 5.590

3.  Novel mutations in SLC16A2 associated with a less severe phenotype of MCT8 deficiency.

Authors:  Silvia Masnada; Stefan Groenweg; Veronica Saletti; Luisa Chiapparini; Barbara Castellotti; Ettore Salsano; W Edward Visser; Davide Tonduti
Journal:  Metab Brain Dis       Date:  2019-07-22       Impact factor: 3.584

4.  Application of the adverse outcome pathway concept for investigating developmental neurotoxicity potential of Chinese herbal medicines by using human neural progenitor cells in vitro.

Authors:  Jördis Klose; Lu Li; Xiaohui Fan; Ellen Fritsche; Melanie Pahl; Farina Bendt; Ulrike Hübenthal; Christian Jüngst; Patrick Petzsch; Astrid Schauss; Karl Köhrer; Ping Chung Leung; Chi Chiu Wang; Katharina Koch; Julia Tigges
Journal:  Cell Biol Toxicol       Date:  2022-06-15       Impact factor: 6.691

5.  Allan-Herndon-Dudley Syndrome: A Novel Pathogenic Variant of the SLC16A2 gene.

Authors:  Ramin Beheshti; Justen Aprile; Charles Lee
Journal:  Cureus       Date:  2022-01-31

Review 6.  Endocrine disorders and the neurologic manifestations.

Authors:  Jeesuk Yu
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-12-31

Review 7.  Monocarboxylate Transporter 8 Deficiency: Delayed or Permanent Hypomyelination?

Authors:  Pieter Vancamp; Barbara A Demeneix; Sylvie Remaud
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-13       Impact factor: 5.555

8.  The Protein Translocation Defect of MCT8L291R Is Rescued by Sodium Phenylbutyrate.

Authors:  Doreen Braun; Ulrich Schweizer
Journal:  Eur Thyroid J       Date:  2020-07-08

9.  Pharmacological treatment and BBB-targeted genetic therapy for MCT8-dependent hypomyelination in zebrafish.

Authors:  David Zada; Adi Tovin; Tali Lerer-Goldshtein; Lior Appelbaum
Journal:  Dis Model Mech       Date:  2016-09-23       Impact factor: 5.758

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.